Hosokawa A, et al. - In patients with advanced gastric cancer, researchers gauged the utility of S-1 plus cisplatin alternating with S-1 plus docetaxel as first-line treatment by conducting a phase I/II study to assess the maximum tolerated dose and recommended dose and evaluate efficacy and toxicity. In the first-line treatment of patients with advanced gastric cancer, they enrolled patients with histologically confirmed unresectable and recurrent gastric cancer. Seemingly the activity seen with this alternating treatment is promising with tolerable and manageable toxicities. Neutropenia, leucopenia, and anemia were the most common grade 3/4 toxicities.